You are here

Senate to Probe EpiPen Pricing

Mylan is on the hot seat

The Senate’s Permanent Subcommittee on Investigations plans to look into the pricing and competition practices of Mylan Pharmaceuticals, the company responsible for hefty price increases on the EpiPen, according to Senators Rob Portman (R-Ohio) and Claire McCaskill (D-Missouri), the chairman and top Democrat on the committee, respectively.

The senators issued the following press announcement:

“The Permanent Subcommittee on Investigations has opened a preliminary inquiry concerning Mylan Pharmaceuticals’ pricing and competition practices with respect to the EpiPen. Our review of this matter will be robust, thorough, and bipartisan. Parents and school districts in Ohio, Missouri, and across the country need affordable access to this life-saving drug, and we share their concern over Mylan’s sustained price increases.”

Since news of Mylan’s 400% price hike emerged, several senators have written to the company asking for information on the reason for the spike.

Senators Amy Klobuchar (D-Minnesota) and Richard Blumenthal (D-Connecticut) asked the Federal Trade Commission to investigate whether Mylan improperly hindered competition for the generic drug through exclusive contracts with schools for getting discounted EpiPens. The New York attorney general has also started an investigation into those contracts.

The House is also scrutinizing Mylan. The House Oversight Committee has called for Mylan executives to brief the committee and answer questions about the hike.

Sources: Washington Examiner; September 7, 2016; and Senator Rob Portman; September 7, 2016.

Recent Headlines

New Hematologic Biomarker Test Provides New Approach to Sepsis Triage and Diagnosis
Antibiotics, Statins, and Glucocorticoids All Show Promise
Possible First Treatment Option for Rare Autoimmune Disease of the CNS
Current, Sole Therapy Not Always Successful/Suitable
Over 1.5 Million Americans Likely to have Wet AMD by 2020 
Potential For Use Against E. Coli, TB, Resistant Bacteria
More Than 32% of Patients Responded in Trial